LN
65 programs · 62 companies
Programs
65
Companies
62
Trials
62
MOAs
43
KIF18AiDLL3 ADCCAR-T BCMAWRNiJAK1/2iMDM2iSGLT2iTNFiWEE1iSTINGag
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8482 | Phase 1 | BTK | ||
| NVS-4076 | Preclinical | TROP-2 | ||
| NVO-9087 | Phase 1/2 | Tau | ||
| GSK-4334 | Preclinical | CD47 | ||
| Motavorutinib | Phase 3 | CDK4/6 | ||
| GIL-2037 | Approved | KRASG12D | ||
| Motazanubrutinib | Preclinical | CD38 | ||
| ALN-5628 | Phase 1/2 | APOC3 | ||
| Ribozanubrutinib | Approved | GPRC5D | ||
| GMA-1468 | NDA/BLA | PI3Kα | ||
| Miritinib | Phase 3 | TIGIT | ||
| Gozeosocimab | Phase 2 | BCMA | ||
| RVM-3746 | Phase 1/2 | GPRC5D | ||
| Zenorelsin | NDA/BLA | JAK2 | ||
| VYG-2970 | Phase 3 | JAK1 | ||
| Adagralucimab | NDA/BLA | CD123 | ||
| Polasertib | Phase 1 | RET | ||
| CSL-8153 | Approved | CD3 | ||
| CSL-4765 | Phase 1/2 | FcRn | ||
| Sovafotisoran | NDA/BLA | FGFR | ||
| Doxafotisoran | NDA/BLA | TIM-3 | ||
| MIR-8648 | Phase 1/2 | GLP-1R | ||
| CHI-3786 | Phase 2 | SOS1 | ||
| Lisozumab | NDA/BLA | JAK2 | ||
| VES-7360 | Approved | MET | ||
| Motarasimod | Phase 1 | KIF18A | ||
| Talacapivasertib | Phase 1/2 | SOS1 | ||
| Teralemzoparlimab | Phase 2/3 | AuroraA | ||
| PRQ-8250 | Phase 2/3 | RET | ||
| Tixafutibatinib | Phase 1/2 | USP1 | ||
| APT-1263 | Phase 1 | VEGF | ||
| AAD-5814 | Phase 2 | BTK | ||
| NBS-1842 | NDA/BLA | FcRn | ||
| Tezesotorasib | Preclinical | SHP2 | ||
| Sovafutibatinib | NDA/BLA | WEE1 | ||
| Niracilimab | Phase 3 | CD19 | ||
| Ivotapinarof | Approved | FGFR | ||
| Nirasertib | Phase 2 | CD20 | ||
| Voxatapinarof | Phase 2 | PARP | ||
| COR-2320 | Preclinical | WEE1 | ||
| Rimavorutinib | Phase 2 | Aβ | ||
| Zenoglumide | Phase 2 | USP1 | ||
| DYN-1761 | Phase 1 | CDK4/6 | ||
| Olpasertib | Preclinical | MDM2 | ||
| Nirarasimod | Phase 2/3 | PARP | ||
| BIO-4284 | Phase 2/3 | PSMA | ||
| Lisotinib | Approved | SGLT2 | ||
| Geliderotide | Phase 2 | SMN2 | ||
| VAL-183 | Phase 2 | PRMT5 | ||
| URG-417 | NDA/BLA | EZH2 | ||
| ESC-2069 | Phase 1/2 | FGFR | ||
| Gelinaritide | Phase 1/2 | FXIa | ||
| Miriratamab | NDA/BLA | DLL3 | ||
| PHA-5173 | Phase 3 | TIGIT | ||
| Lisotapinarof | NDA/BLA | CD38 | ||
| PET-IIT-604 | NDA/BLA | AuroraA | ||
| CAN-IIT-986 | NDA/BLA | SGLT2 | ||
| SQU-6405 | Phase 2/3 | VEGF | ||
| Teratinib | NDA/BLA | PD-L1 | ||
| Nidaratamab | Approved | C5 | ||
| TEC-1111 | Phase 1/2 | B7-H3 | ||
| Olpazumab | Phase 1/2 | EGFR | ||
| EGI-7413 | Phase 1 | PRMT5 | ||
| Ivosotorasib | Phase 2/3 | EZH2 | ||
| Cevisotorasib | Phase 2/3 | HER2 |
Trials (62)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06039090 | GSK-4334 | Preclinical | Not yet recr... |
| NCT05932693 | GSK-4334 | Preclinical | Recruiting |
| NCT08560224 | Motavorutinib | Phase 3 | Completed |
| NCT07161792 | GIL-2037 | Approved | Not yet recr... |
| NCT03201210 | Motazanubrutinib | Preclinical | Active |
| NCT05543927 | Motazanubrutinib | Preclinical | Not yet recr... |
| NCT08881430 | ALN-5628 | Phase 1/2 | Terminated |
| NCT03009997 | Gozeosocimab | Phase 2 | Recruiting |
| NCT08668935 | RVM-3746 | Phase 1/2 | Active |
| NCT07432264 | VYG-2970 | Phase 3 | Active |
| NCT03972083 | VYG-2970 | Phase 3 | Recruiting |
| NCT05295043 | VYG-2970 | Phase 3 | Recruiting |
| NCT04971313 | Adagralucimab | NDA/BLA | Not yet recr... |
| NCT05237230 | Polasertib | Phase 1 | Terminated |
| NCT07331355 | CSL-8153 | Approved | Terminated |
| NCT05964807 | CSL-8153 | Approved | Active |
| NCT04348062 | CSL-4765 | Phase 1/2 | Terminated |
| NCT06007171 | CSL-4765 | Phase 1/2 | Terminated |
| NCT04473564 | Doxafotisoran | NDA/BLA | Not yet recr... |
| NCT03513961 | Lisozumab | NDA/BLA | Completed |